docs (beta)

42.0.0.26 – Redirect Fix (Removed pre-redirect output)
DEBUG LOG – klik om te openen 
=== VARIABELEN ===
Array
(
    [defid] => VWS-WOO-08-1254347
    [request_id] => 
)

=== SQL LOG ===
Geen SQL queries.
Huidig document record 
Array
(
    [id] => 8015a6a7-c2cb-432f-8c0d-9c71ec0086b2
    [Document ID] => 1254347
    [Document naam] => RE: AstraZeneca - AZD1222 US Phase III trial met primary efficacyendpoint in preventing COVID-19 at interim analysis
    [Bestandsnaam] => 
    [Beoordeling] => 
    [Beoordelingsgrond] => 
    [Toelichting] => 
    [Publieke link] => 
    [Locatie open.minvws.nl] => https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/document/VWS-WOO-08-1254347
    [Opgeschort] => 
    [Definitief ID] => VWS-WOO-08-1254347
    [Status] => 
    [FromFile] => https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo
    [DocumentPublicationDate] => 22 maart 2021
    [DocumentStatusCheckedDate] => 
    [DocumentStatusCheckedResult] => 
    [SourceFileType] => 
    [Tags] => 
    [Besluit] => 
    [ModifiedDate] => 2025-09-21 14:20:22
    [DeletedDate] => 
    [BesluitURL] => 
    [CreatedDate] => 2025-06-19 18:31:59
    [DocumentDownloadLink] => 
    [DigestLaatsteControleDatum] => 2025-09-21 14:20:22
)

Document: VWS-WOO-08-1254347

Pagina 1 preview
Klik om te vergroten

Document correcties

Geregistreerde datum: 20210322

Geregistreerde documentnaam: RE: AstraZeneca - AZD1222 US Phase III trial met primary efficacyendpoint in preventing COVID-19 at interim analysis

Document metadata

Metadata tonen (25 velden)
VeldWaarde
id8015a6a7-c2cb-432f-8c0d-9c71ec0086b2
Document ID1254347
Document naamRE: AstraZeneca - AZD1222 US Phase III trial met primary efficacyendpoint in preventing COVID-19 at interim analysis
Bestandsnaamleeg!
Beoordelingleeg!
Beoordelingsgrondleeg!
Toelichtingleeg!
Publieke linkleeg!
Locatie open.minvws.nlhttps://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/document/VWS-WOO-08-1254347
Opgeschortleeg!
Definitief IDVWS-WOO-08-1254347
Statusleeg!
FromFilehttps://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo
DocumentPublicationDate22 maart 2021
DocumentStatusCheckedDateleeg!
DocumentStatusCheckedResultleeg!
SourceFileTypeleeg!
Tagsleeg!
Besluitleeg!
ModifiedDate2025-09-21 14:20:22
DeletedDateleeg!
BesluitURLleeg!
CreatedDate2025-06-19 18:31:59
DocumentDownloadLinkleeg!
DigestLaatsteControleDatum2025-09-21 14:20:22

🧙 User tags

Nog geen user tags

Document attributen

TagWaardeDatum
About_Gelakte gegevens_linkhref_2mailto:DienstpostbusDatalekkenDoo@minvws.nl2025-09-01 11:51:11
About_Gelakte gegevens5.1.2e Eerbiediging van de persoonlijke levenssfeer Komt u in dit document gegevens tegen waarvan u denkt dat deze gelakt hadden moeten worden? Of is het document slecht leesbaar? Laat het ons weten2025-09-01 11:51:11
document_SectionDownloadButton12025-07-11 05:57:45
DocumentDownload_proposed_filename (lokale kopie)VWS-WOO-08-1254347.pdf2025-07-11 05:57:45
DocumentDownload_linkhrefhttps://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/file/download/document/1eec1b43-4d38-644e-ace4-bb3705657b162025-07-11 05:57:45
DocumentDownload_linknameDownload (pdf, 1.67 MB)2025-07-11 05:57:45
document_SectionHistory12025-06-22 23:45:23
About_Gelakte gegevens_linkhref_2mailto:_dienstpostbusWoo-corona-ondersteuning@minvws.nl?subject=Opmerking over RE: AstraZeneca - AZD1222 US Phase III trial met primary efficacyendpoint in preventing COVID-19 at interim analysis (documentnummer 1eec1b43-4d38-644e-ace4-bb3705657b16)2025-06-22 23:45:23
About_Gelakte gegevens_linkname_2Laat het ons weten2025-06-22 23:45:23
document_SectionLinked12025-06-22 23:45:23
document_SectionRequest12025-06-22 23:45:23
Request_Onderdeel vanWoo-deelbesluit aangaande Vaccinaties en Medicatie over de periode maart 20212025-06-22 23:45:23
Request_Onderdeel van_linkhref_1https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo2025-06-22 23:45:23
Request_Onderdeel van_linkname_1Woo-deelbesluit aangaande Vaccinaties en Medicatie over de periode maart 20212025-06-22 23:45:23
Request_Samenvatting verzoekDe minister van Volksgezondheid, Welzijn en Sport heeft op 23 november 2023 een besluit genomen op verzoeken in het kader van de Wet open overheid. Het besluit betreft openbaarmaking van documenten die betrekking hebben op informatie aangaande Vaccinaties & Medicatie maart 2021.2025-06-22 23:45:23
Request_PeriodeMaart 20212025-06-22 23:45:23
Request_Type besluitWoo-besluit2025-06-22 23:45:23
Request_Datum besluit23 november 20232025-06-22 23:45:23
Request_Omvang openbaarmaking15.961 documenten, 29.047 pagina's Inventarislijst2025-06-22 23:45:23
Request_Omvang openbaarmaking_documenten15.9612025-06-22 23:45:23
Request_Omvang openbaarmaking_paginas29.0472025-06-22 23:45:23
Request_Omvang openbaarmaking_linkhref_1https://open.minvws.nl/dossier/VWS-WOO/3661708-1052463-pdo/file/download/inventory2025-06-22 23:45:23
Request_Omvang openbaarmaking_linkname_1Inventarislijst2025-06-22 23:45:23
document_documentNameRE: AstraZeneca - AZD1222 US Phase III trial met primary efficacyendpoint in preventing COVID-19 at interim analysis2025-06-22 23:45:23
document_documentTypeE-mailbericht2025-06-22 23:45:23
document_documentPublicationDate2021-03-222025-06-22 23:45:23
document_documentNumberVWS-WOO-08-12543472025-06-22 23:45:23
document_SectionDownloadButton02025-06-22 23:45:23
document_SectionHTMLDataDivs42025-06-22 23:45:23
document_SectionAbout12025-06-22 23:45:23
About_Datum document22 maart 20212025-06-22 23:45:23
About_Type bronbestandE-mailbericht, 3 pagina's2025-06-22 23:45:23
About_Type bronbestand_paginas32025-06-22 23:45:23
About_Download alsPDF (1.67 MB)2025-06-22 23:45:23
About_Documentnummer12543472025-06-22 23:45:23
About_BeoordelingGedeeltelijke openbaarmaking2025-06-22 23:45:23
About_Gelakte gegevens5.1.2e Eerbiediging van de persoonlijke levenssfeer Komt u in dit document gegevens tegen waarvan u denkt dat deze gelakt hadden moeten worden? Of is het document slecht leesbaar? Laat het ons weten.2025-06-22 23:45:23
About_Gelakte gegevens_linkhref_1https://wetten.overheid.nl/BWBR0045754/2022-08-01#Hoofdstuk52025-06-22 23:45:23
About_Gelakte gegevens_linkname_15.1.2e Eerbiediging van de persoonlijke levenssfeer2025-06-22 23:45:23
History Actie_4Bronbestand vervangen (pdf, 1.67 MB)2025-06-21 06:29:39
History Datum_530 mei 2024 17:002025-06-21 06:29:39
History Actie_5Bronbestand vervangen (pdf, 1.67 MB)2025-06-21 06:29:39
History Datum_630 mei 2024 16:462025-06-21 06:29:39
History Actie_6Bronbestand vervangen (pdf, 1.67 MB)2025-06-21 06:29:39
History Datum_730 mei 2024 15:122025-06-21 06:29:39
History Actie_7Bronbestand vervangen (pdf, 1.67 MB)2025-06-21 06:29:39
History Datum_830 mei 2024 15:002025-06-21 06:29:39
History Actie_8Bronbestand toegevoegd (pdf, 1.67 MB)2025-06-21 06:29:39
History Datum_430 mei 2024 18:312025-06-21 06:29:39
History Actie_3Bronbestand vervangen (pdf, 1.67 MB)2025-06-21 06:29:39
History Datum_330 mei 2024 18:452025-06-21 06:29:39
History Actie_2Bronbestand vervangen (pdf, 1.67 MB)2025-06-21 06:29:39
History Datum_230 mei 2024 19:242025-06-21 06:29:39
History Actie_1Bronbestand vervangen (pdf, 1.67 MB)2025-06-21 06:29:39
History Datum_130 mei 2024 19:282025-06-21 06:29:39

Archiefversies (6 rijen)

Archiefrij 1 — 2025-09-07 17:26:20
fromFile: folder_import
fromFilePath: /volume3/websites/openrijksoverheid/documenten_files/VWS-WOO-08-1254347.pdf
documentName: VWS-WOO-08-1254347.pdf
documentType: pdf
documentCompressedSize: 0
documentSize: 1750031
documentCompressRatio: 0
documentDateModified: 2025-09-07 17:26:20
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-07 17:26:20
lastSeen: 2025-09-07 17:26:20
text: 1254347 @minvws.nl @minvws.nl]; EAE r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon 3/22/2021 10:45:06 AM Subject: RE: AstraZeneca-AZD1222 USPhase llltrial met primary efficacyendpoint inpreventing COVID-19 atinterim analysis Received:Mon 3/22/2021 10:45:08 AM Interessant, dank voor doorsturen Alsje...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: b4fb8fc45f407a3bcee5d8279e5b13f5196c57ac66a7085100065d40dae88607
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: folder_import_48795_00da29ce2e3dc10af663e856f5f06710
textDigestSHA256: 3bff970506a9f0f01d6f99672001ea1c13c4a1f3278737fa46435662faaf3f7b
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1254347
Archiefrij 2 — 2025-09-04 17:12:23
fromFile: VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip
fromFilePath: ../../archieven_files/VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip
documentName: VWS-WOO-08-1254347.pdf
documentType: pdf
documentCompressedSize: 1323473
documentSize: 1750031
documentCompressRatio: 75.62568891636778
documentDateModified: 2025-05-01 20:32:30
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-04 17:12:23
lastSeen: 2025-09-04 17:12:23
text: 1254347 @minvws.nl @minvws.nl]; 5.1.2e EAE r-CE) @minvws.nl]; BEES [EAE @rivm.nl] Mon 3/22/2021 10:45:06 AM RE: AstraZeneca Subject: - AZD1222 US Phase lll trial met primary efficacyendpoint in preventing COVID-19 at interim analysis Mon 3/22/2021 10:45:08 AM Rec...
noTextDate: leeg!
ocrText: 1227720 Artikel ArtikeIType, ArtikelFarmaceut ArtikelDescription ArtikelCategorie ArtikelAantal ArtikelEenheid, ArtikelHoeveelheid, ArtikelHoeveelheid Flacons,ArtikelHoeveelheidDosesPerTray ArtikelHoeveelheidDoses, ArtikelAfnemer ArtikelAfnemerGroep, ArtikelAfgiftedatum , ArtikelStatus, ArtikelAfze...
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: b4fb8fc45f407a3bcee5d8279e5b13f5196c57ac66a7085100065d40dae88607
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:10.749631+00
Id: VWS-WOO-3661708-1052463-pdo-1f026c98-ad58-69b6-b436-65673e0af118.zip_1986
textDigestSHA256: 893c5f99bc299cc3a50c330d8a5cc02a37687902b40e8e0371071eba4ece1a48
ocrTextDigestSHA256: cbb318e36bc801b51a4e835f266ccf9e2f2591f7587882f9cceab6e8131f83fb
extractedId: VWS-WOO-08-1254347
Archiefrij 3 — 2025-09-04 17:10:20
fromFile: VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip
fromFilePath: ../../archieven_files/VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip
documentName: VWS-WOO-08-1254347.pdf
documentType: pdf
documentCompressedSize: 1323473
documentSize: 1750031
documentCompressRatio: 75.62568891636778
documentDateModified: 2025-05-01 20:32:30
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-09-04 17:10:20
lastSeen: 2025-09-04 17:10:20
text: 1254347 @minvws.nl @minvws.nl]; 5.1.2e EAE r-CE) @minvws.nl]; BEES [EAE @rivm.nl] Mon 3/22/2021 10:45:06 AM RE: AstraZeneca Subject: - AZD1222 US Phase lll trial met primary efficacyendpoint in preventing COVID-19 at interim analysis Mon 3/22/2021 10:45:08 AM Rec...
noTextDate: leeg!
ocrText: isoweek-2021 isoweek-2022 |Ct-waarde 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-09 2022-...
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: b4fb8fc45f407a3bcee5d8279e5b13f5196c57ac66a7085100065d40dae88607
documentDate: leeg!
ModifiedDate: 2025-12-10 19:42:20.178639+00
Id: VWS-WOO-3661708-1052463-pdo-1f019da5-31c3-6fd4-91a7-fda7571a98e0.zip_1986
textDigestSHA256: 893c5f99bc299cc3a50c330d8a5cc02a37687902b40e8e0371071eba4ece1a48
ocrTextDigestSHA256: 34ea7743594f08b217c2e155c1f4035ef17e172d69327d310aa73507055b967b
extractedId: VWS-WOO-08-1254347
Archiefrij 4 — 2025-03-18 09:30:26
fromFile: 2024.075-VWS-WOO-3661708-1052463-pdo.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\2024.075-VWS-WOO-3661708-1052463-pdo.zip
documentName: VWS-WOO-08-1254347-RE_AstraZeneca_-_AZD1222_US_Phase_III_trial_met_primary_efficacyendpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 1320832
documentSize: 1750031
documentCompressRatio: 75.4747773039449
documentDateModified: 2024-10-25 13:31:38
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-03-18 09:30:26
lastSeen: 2025-03-18 09:30:26
text: 1254347 @minvws.nl @minvws.nl]; EAE r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon 3/22/2021 10:45:06 AM Subject: RE: AstraZeneca-AZD1222 USPhase llltrial met primary efficacyendpoint inpreventing COVID-19 atinterim analysis Received:Mon 3/22/2021 10:45:08 AM Interessant, dank voor doorsturen Alsje...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: leeg!
documentMailAdresses: leeg!
digestSHA256: 3bff970506a9f0f01d6f99672001ea1c13c4a1f3278737fa46435662faaf3f7b
documentDate: leeg!
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: 356254
textDigestSHA256: 3bff970506a9f0f01d6f99672001ea1c13c4a1f3278737fa46435662faaf3f7b
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1254347
Archiefrij 5 — 2025-02-27 09:25:06
fromFile: 2022.252-VWS-WOO-3661708-1052463-pdo.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\2022.252-VWS-WOO-3661708-1052463-pdo.zip
documentName: VWS-WOO-08-1254347-RE_AstraZeneca_-_AZD1222_US_Phase_III_trial_met_primary_efficacyendpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 1320832
documentSize: 1750031
documentCompressRatio: 75.4747773039449
documentDateModified: 2024-10-25 13:31:38
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-02-27 09:25:06
lastSeen: 2025-02-27 09:25:06
text: 1254347 @minvws.nl @minvws.nl]; EAE r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon 3/22/2021 10:45:06 AM Subject: RE: AstraZeneca-AZD1222 USPhase llltrial met primary efficacyendpoint inpreventing COVID-19 atinterim analysis Received:Mon 3/22/2021 10:45:08 AM Interessant, dank voor doorsturen Alsje...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: [{"position": 8, "email": "@minvws.nl", "context": "1254347 @minvws.nl @minvws.nl]; EAE r-CE)"}, {"position": 19, "email": "@minvws.nl", "context": "1254347 @minvws.nl @minvws.nl]; EAE r-CE) [EAE@minvws.nl];"}, {"position": 43, "email": "EAE@minvws.nl", "context": "@minvws.nl]; EAE r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon"}, {"position": 64, "email": "5.1.2e@rivm.nl", "context": "r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon 3/22/2021 10:45:06"}, {"position": 801, "email": "@minvws.nl", "context": "2021 09:46 Aan:iEEEq @minvws.nl>;Ei205.126 Onderwerp: RE:AstraZeneca-AZD1222 USPhase"}, {"position": 1175, "email": "5.1.2e@rivm.nl", "context": "5.1. ThBEN.ERED) < 5.1.2e@rivm.nl>;ERE 5.1.2e 512e isize"}, {"position": 1251, "email": "@minvws.nl", "context": "512e |: 5.1.2e @minvws.nl> @minvws.nl> Onderwerp: RE:AstraZeneca-AZD1222"}, {"position": 1263, "email": "@minvws.nl", "context": "|: 5.1.2e @minvws.nl> @minvws.nl> Onderwerp: RE:AstraZeneca-AZD1222 USPhase"}, {"position": 1387, "email": "analysis@rivm.nl", "context": "endpointinpreventing COVID-19 atinterim analysis@rivm.nl>; Interessant idd, evt"}, {"position": 1639, "email": "@rivm.nl", "context": "08:541254347 Aan: .5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <}"}, {"position": 1651, "email": "5.1.2e@rivm.nl", "context": "Aan: .5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <} 5.1.2e"}, {"position": 1673, "email": "1.@rivm.nl", "context": ".5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <} 5.1.2e !s122e"}]
documentMailAdresses: [{"position": 8, "email": "@minvws.nl", "context": "1254347 @minvws.nl @minvws.nl]; EAE r-CE)"}, {"position": 19, "email": "@minvws.nl", "context": "1254347 @minvws.nl @minvws.nl]; EAE r-CE) [EAE@minvws.nl];"}, {"position": 43, "email": "EAE@minvws.nl", "context": "@minvws.nl]; EAE r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon"}, {"position": 64, "email": "5.1.2e@rivm.nl", "context": "r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon 3/22/2021 10:45:06"}, {"position": 801, "email": "@minvws.nl", "context": "2021 09:46 Aan:iEEEq @minvws.nl>;Ei205.126 Onderwerp: RE:AstraZeneca-AZD1222 USPhase"}, {"position": 1175, "email": "5.1.2e@rivm.nl", "context": "5.1. ThBEN.ERED) < 5.1.2e@rivm.nl>;ERE 5.1.2e 512e isize"}, {"position": 1251, "email": "@minvws.nl", "context": "512e |: 5.1.2e @minvws.nl> @minvws.nl> Onderwerp: RE:AstraZeneca-AZD1222"}, {"position": 1263, "email": "@minvws.nl", "context": "|: 5.1.2e @minvws.nl> @minvws.nl> Onderwerp: RE:AstraZeneca-AZD1222 USPhase"}, {"position": 1387, "email": "analysis@rivm.nl", "context": "endpointinpreventing COVID-19 atinterim analysis@rivm.nl>; Interessant idd, evt"}, {"position": 1639, "email": "@rivm.nl", "context": "08:541254347 Aan: .5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <}"}, {"position": 1651, "email": "5.1.2e@rivm.nl", "context": "Aan: .5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <} 5.1.2e"}, {"position": 1673, "email": "1.@rivm.nl", "context": ".5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <} 5.1.2e !s122e"}]
digestSHA256: 3bff970506a9f0f01d6f99672001ea1c13c4a1f3278737fa46435662faaf3f7b
documentDate: 2021-03-22
ModifiedDate: 2025-12-10 19:41:04.555019+00
Id: 269424
textDigestSHA256: 3bff970506a9f0f01d6f99672001ea1c13c4a1f3278737fa46435662faaf3f7b
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1254347
Archiefrij 6 — 2025-02-18 12:18:04
fromFile: Besluit__dossier_nr_-8b6498f524850c599dea15620ecff89d59609350ff716d119d38634615d4d862.zip
fromFilePath: Z:\ARCHIEF WOO Documenten\archieven_files\Besluit__dossier_nr_-8b6498f524850c599dea15620ecff89d59609350ff716d119d38634615d4d862.zip
documentName: VWS-WOO-08-1254347-RE_AstraZeneca_-_AZD1222_US_Phase_III_trial_met_primary_efficacyendpoint_in_preventing_COVID-19_at_interim_analysis.pdf
documentType: pdf
documentCompressedSize: 1320832
documentSize: 1750031
documentCompressRatio: 75.4747773039449
documentDateModified: 2024-10-25 13:31:38
dossierReference: leeg!
dossierReferenceAlias: leeg!
createdDate: 2025-02-18 12:18:04
lastSeen: 2025-02-18 12:18:04
text: 1254347 @minvws.nl @minvws.nl]; EAE r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon 3/22/2021 10:45:06 AM Subject: RE: AstraZeneca-AZD1222 USPhase llltrial met primary efficacyendpoint inpreventing COVID-19 atinterim analysis Received:Mon 3/22/2021 10:45:08 AM Interessant, dank voor doorsturen Alsje...
noTextDate: leeg!
ocrText: leeg!
documentIndicatedDate: leeg!
documentIndicatedDateCorrected: leeg!
documentMailAddresses: [{"position": 8, "email": "@minvws.nl", "context": "1254347 @minvws.nl @minvws.nl]; EAE r-CE)"}, {"position": 19, "email": "@minvws.nl", "context": "1254347 @minvws.nl @minvws.nl]; EAE r-CE) [EAE@minvws.nl];"}, {"position": 43, "email": "EAE@minvws.nl", "context": "@minvws.nl]; EAE r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon"}, {"position": 64, "email": "5.1.2e@rivm.nl", "context": "r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon 3/22/2021 10:45:06"}, {"position": 801, "email": "@minvws.nl", "context": "2021 09:46 Aan:iEEEq @minvws.nl>;Ei205.126 Onderwerp: RE:AstraZeneca-AZD1222 USPhase"}, {"position": 1175, "email": "5.1.2e@rivm.nl", "context": "5.1. ThBEN.ERED) < 5.1.2e@rivm.nl>;ERE 5.1.2e 512e isize"}, {"position": 1251, "email": "@minvws.nl", "context": "512e |: 5.1.2e @minvws.nl> @minvws.nl> Onderwerp: RE:AstraZeneca-AZD1222"}, {"position": 1263, "email": "@minvws.nl", "context": "|: 5.1.2e @minvws.nl> @minvws.nl> Onderwerp: RE:AstraZeneca-AZD1222 USPhase"}, {"position": 1387, "email": "analysis@rivm.nl", "context": "endpointinpreventing COVID-19 atinterim analysis@rivm.nl>; Interessant idd, evt"}, {"position": 1639, "email": "@rivm.nl", "context": "08:541254347 Aan: .5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <}"}, {"position": 1651, "email": "5.1.2e@rivm.nl", "context": "Aan: .5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <} 5.1.2e"}, {"position": 1673, "email": "1.@rivm.nl", "context": ".5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <} 5.1.2e !s122e"}]
documentMailAdresses: [{"position": 8, "email": "@minvws.nl", "context": "1254347 @minvws.nl @minvws.nl]; EAE r-CE)"}, {"position": 19, "email": "@minvws.nl", "context": "1254347 @minvws.nl @minvws.nl]; EAE r-CE) [EAE@minvws.nl];"}, {"position": 43, "email": "EAE@minvws.nl", "context": "@minvws.nl]; EAE r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon"}, {"position": 64, "email": "5.1.2e@rivm.nl", "context": "r-CE) [EAE@minvws.nl]; BEES 5.1.2e@rivm.nl] Mon 3/22/2021 10:45:06"}, {"position": 801, "email": "@minvws.nl", "context": "2021 09:46 Aan:iEEEq @minvws.nl>;Ei205.126 Onderwerp: RE:AstraZeneca-AZD1222 USPhase"}, {"position": 1175, "email": "5.1.2e@rivm.nl", "context": "5.1. ThBEN.ERED) < 5.1.2e@rivm.nl>;ERE 5.1.2e 512e isize"}, {"position": 1251, "email": "@minvws.nl", "context": "512e |: 5.1.2e @minvws.nl> @minvws.nl> Onderwerp: RE:AstraZeneca-AZD1222"}, {"position": 1263, "email": "@minvws.nl", "context": "|: 5.1.2e @minvws.nl> @minvws.nl> Onderwerp: RE:AstraZeneca-AZD1222 USPhase"}, {"position": 1387, "email": "analysis@rivm.nl", "context": "endpointinpreventing COVID-19 atinterim analysis@rivm.nl>; Interessant idd, evt"}, {"position": 1639, "email": "@rivm.nl", "context": "08:541254347 Aan: .5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <}"}, {"position": 1651, "email": "5.1.2e@rivm.nl", "context": "Aan: .5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <} 5.1.2e"}, {"position": 1673, "email": "1.@rivm.nl", "context": ".5.1.2\u00a2| @rivm.nl>; |5.1.2e@rivm.nl>;SP1.2 1.@rivm.nl>; <} 5.1.2e !s122e"}]
digestSHA256: 3bff970506a9f0f01d6f99672001ea1c13c4a1f3278737fa46435662faaf3f7b
documentDate: 2021-03-22
ModifiedDate: 2025-12-10 19:40:42.137456+00
Id: 58560
textDigestSHA256: 3bff970506a9f0f01d6f99672001ea1c13c4a1f3278737fa46435662faaf3f7b
ocrTextDigestSHA256: leeg!
extractedId: VWS-WOO-08-1254347
Nieuw document zoeken

(dit is ook een speeltuin)